Durham, Jennifer N.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 6,645

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity

Ho, W. J., Zhu, Q., Durham, J., Popovic, A., Xavier, S., Leatherman, J., Mohan, A., Mo, G., Zhang, S., Gross, N., et al. (2021) · Nature Cancer

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 360

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma

Hopkins, A. C., Yarchoan, M., Durham, J. N., Yusko, E. C., Rytlewski, J. A., Robins, H. S., Laheru, D. A., Le, D. T., Lutz, E. R., & Jaffee, E. M. (2018) · JCI Insight

Cancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology Research

Cited by 233

Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma

Christenson, E. S., Lim, S. J., Durham, J., De Jesus-Acosta, A., Bever, K., Laheru, D., Ryan, A., Agarwal, P., Scharpf, R. B., Le, D. T., et al. (2022) · Cancer Research Communications

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 12

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer

Wilbur, H. C., Durham, J. N., Lim, S. J., Purtell, K., Bever, K. M., Laheru, D. A., De Jesus-Acosta, A., Azad, N. S., Wilt, B., Diaz, L. A., et al. (2023) · Cancer Research Communications

Pancreatic and Hepatic Oncology ResearchCancer Treatment and Pharmacology

Cited by 9